Telehealth & Controlled Substances: DEA Extends Flexibilities | 2024 Update

WASHINGTON, April 25, 2024 – If you’ve filled a prescription via a video visit with your doctor, listen up. The ability to do so for controlled substances-think medications for ADHD, anxiety, or pain-has been temporarily extended yet again. This continuation of a pandemic-era policy is a big deal for millions who’ve come to rely on the convenience of telehealth.

Telehealth Prescribing: What’s Changing?

The rules around prescribing medications virtually are evolving, impacting access to care.

KEY TAKEAWAYS

• The temporary extension allows continued telehealth prescribing of controlled substances.
• Two new virtual prescribing rules have been implemented.
• The extension provides time for further evaluation of telehealth’s role in healthcare.

The fourth temporary extension continues the status quo of controlled substance prescribing via telehealth since 2020. But it doesn’t stop there. The changes also put into effect two other virtual prescribing rules.

What does this mean for patients? telehealth prescribing, notably for controlled substances, remains accessible, but under continued review. The Drug enforcement Administration (DEA) initially allowed expanded telehealth prescribing during the COVID-19 public health emergency, recognizing the need for remote access to care.

A History of Temporary Rules

The initial versatility granted during the pandemic was set to expire, prompting concerns about access to care, especially for those in rural areas or with limited mobility. The DEA has since issued a series of temporary extensions while it develops permanent rules.This latest extension provides more time for that process.

Did you know? the DEA is currently considering proposed rules that would establish different approaches to telehealth prescribing, including requiring an initial in-person visit.

What are the New Virtual prescribing Rules?

Beyond the extension of controlled substance prescribing, the new rules address other aspects of virtual healthcare. details on these specific rules were not immediately available, but they signal a broader effort to refine the regulations surrounding telehealth. The DEA aims to strike a balance between expanding access to care and ensuring patient safety.

The DEA’s ongoing evaluation of telehealth prescribing is a complex undertaking. It involves weighing the benefits of convenience and accessibility against the risks of potential misuse or diversion of medications. the agency is seeking input from stakeholders, including healthcare providers, patients, and law enforcement officials, as it develops its long-term strategy.

Share your thoughts on the future of telehealth in the comments below!